| Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trials. | |
| | |
MedLine Citation:
|
PMID: 19012496 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Over 10 years after their approval as cancer supportive and palliative care agents, erythropoietin and the bisphosphonates began to show unexpected, serious adverse events, which resulted in dramatic changes in how they were subsequently prescribed to cancer patients. OBJECTIVE: The purpose of this opinion piece is to reexamine what happened. METHODS: We relied on the published literature as well as the investigators' own experience and preliminary data. CONCLUSION: The importance of adverse event reporting in cancer supportive and palliative agents should go beyond that which is mandated by the Food and Drug Administration (FDA). Funding agencies and practicing oncologists should remain vigilant for such adverse events during the testing of new agents and after their approval. They should be willing to report such events without delay. |
| | |
Authors:
|
Aminah Jatoi; Phuong L Nguyen |
Related Documents
:
|
21879266 - Increased cd13 expression reduces reactive oxygen species, promoting survival of liver ... 18763256 - Selenium and the prevention of prostate and colorectal cancer. 1434646 - Biological monitoring of cancer chemoprevention. 21820706 - Prostate cancer risk alleles and their associations with other malignancies. 7684076 - Expression of large intestinal mucin antigen (lima) epitopes in the normal and neoplast... 9439756 - Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 17 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-11-17 Completed Date: 2009-01-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1787-90 Citation Subset: IM |
Affiliation:
|
Mayo Clinic, Departments of Oncology, 200 First Street SW, Rochester, Minnesota 55905, USA. jatoi.aminah@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects*,
therapeutic use* Diphosphonates / therapeutic use Erythropoietin / therapeutic use Humans Neoplasms / drug therapy* Palliative Care* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Diphosphonates; 11096-26-7/Erythropoietin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter.
Next Document: Discontinued drugs in 2007: oncology drugs.